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Abstract
Background Ethyl glucuronide (EtG) and ethyl sulfate (EtS)
are non-oxidative minor metabolites of ethanol. They are
detectable in various body fluids shortly after initial consump-
tion of ethanol and have a longer detection time frame than the
parent compound. They are regarded highly sensitive and
specific markers of recent alcohol uptake. This study evaluates
the determination of EtG and EtS from dried blood spots
(DBS), a simple and cost-effective sampling method that
would shorten the time gap between offense and blood sam-
pling and lead to a better reflectance of the actual impairment.
Methods For method validation, EtG and EtS standard and
quality control samples were prepared in fresh human hep-
arinized blood and spotted on DBS cards, then extracted and
measured by an LC-ESI-MS/MS method. Additionally, 76
heparinized blood samples from traffic offense cases were
analyzed for EtG and EtS as whole blood and as DBS
specimens. The results from these measurements were then
compared by calculating the respective mean values, by a
matched-paired t test, by a Wilcoxon test, and by Bland–
Altman and Mountain plots.
Results and discussion Calibrations for EtG and EtS in DBS
were linear over the studied calibration range. The precision
and accuracy of the method met the requirements of the vali-
dation guidelines that were employed in the study. The stability
of the biomarkers stored as DBS was demonstrated under
different storage conditions. The t test showed no significant
difference between whole blood and DBS in the determination
of EtG and EtS. In addition, the Bland–Altman analysis and
Mountain plot confirmed that the concentration differences that
were measured in DBS specimens were not relevant.
Keywords Ethyl glucuronide . Ethyl sulfate . Alcohol
markers . Dried blood spots . LC-ESI-MS/MS .
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Introduction
Ethyl glucuronide and ethyl sulfate are direct alcohol markers
which are widely used for clinical, forensic and traffic cases,
and in workplace monitoring [1–3]. Apart from being highly
sensitive and specific in comparison with other traditional
biomarkers [4, 5], they are detectable in various matrices, each
of them with a different detection window. Depending on the
ethanol uptake, ethyl glucuronide (EtG) and ethyl sulfate
(EtS) are detectable in blood for up to 8 h, in urine for up to
4 days [6–9], and in hair for up to several months depending
on the hair length [10], even when ethanol is no longer
detectable. For those reasons, EtG and EtS are getting more
and more popular not only for the detection of recent alcohol
consumption (blood, urine) [8] but also for the determination
of chronic alcohol abuse (hair, nails) [11, 12].
For decades, filter paper was used to collect and analyze
human blood in form of dried blood spots (DBS) for neonatal
metabolic screening [13, 14]. However, it was only in the last
two decades that the methodwas accepted for therapeutic drug
monitoring [15, 16] and the detection of drugs of abuse
[17–19]. The advantages of DBS include the small volume
of sample that is necessary (between 10 and 100 μL), the less
invasive sample collection method, and an easier and more
economic transport and storage of specimens: cooling or
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special biohazard arrangements are not necessary due to the
stability of most analytes in DBS and the reduction of a virus
infection risk [20–22]. Despite the advantages of DBS over
conventional whole blood analysis, some doubts have arisen
in the scientific community about the viability of the method
for quantitative determination of drug concentration in a reg-
ulated environment [23]. The most delicate factors of the
method are the influence of the hematocrit value and the
application mode of the isotopically labeled internal standards
on the determination of the analytes [24–26]. Some authors
also distrust some of the so-called advantages of the DBS
method since the small sample volumes require very sensitive
instruments for determination of the analytes and also see
challenges with incurred sample reanalysis.
In this study, the viability of the DBS method for EtG and
EtS determination was evaluated following some recent
reports about the applicability of this technique for monitor-
ing alcohol consumption [27, 28] and in analogy to a recent
publication where EtG and EtS were determined from dried
urine spots [29]. Further, the method was validated accord-
ing to the guidelines of the German Society of Toxicological
and Forensic Chemistry (GTFCh) [30]. A statistical com-
parison was also performed with 76 heparinized blood sam-
ples from traffic offense cases that were analyzed as whole
blood and as DBS.
Experimental
Analytical methods
Preparation of calibration and quality control samples
Stock solutions of EtG and EtS (1 mg/mL) were prepared in
pure methanol and used to prepare the working solutions also
in methanol for spiking of calibration and quality control (QC)
samples. Calibration standards were prepared on a daily basis
by spiking blank human whole blood at concentration levels
of 0.1, 0.2, 1.0, 2.5, 5.0, and 10 μg/mL. Quality control
samples were prepared at EtG and EtS concentrations of
0.3 μg/mL (QClow) and 6.6 μg/mL (QChigh).
Processing of whole blood samples
Fifty microliters of blood (calibrators and samples) was trans-
ferred to an Eppendorf tube and 150 μL of acetonitrile that
contained internal standards (IS) (0.66 μg/mL pentadeuterated
EtG (D5-EtG), ca. 0.05 μg/mL D5-EtS) was added. The sam-
ples were mixed by vortexing for 10 min and finally centri-
fuged for 10 min at 18,320×g. One hundred microliters of the
supernatant solutions were then transferred into 200-μL re-
stricted volume autosampler glass vials and evaporated under
a gentle stream of nitrogen at 50 °C. The residues were
reconstituted with 100 μL of a water/acetonitrile/formic acid
(95/5/0.1; v/v) solution and shaken for 1 min before injection
of 10 μL into the LC-MS/MS system.
Preparation and processing of DBS samples
For each sample (calibration, quality control, unknown),
10 μL of blood (instead of 50 μL in whole blood samples)
was pipetted onto the center of a printed circle on 226-1004
Bioanalysis cards, where they diffused and dried for at least
3 h at ambient room temperature prior to further analysis.
The whole DBS was punched out using a 1-cm-diameter
hole puncher and collected in an Eppendorf tube. The ex-
traction of the analytes was performed by adding 500 μL of
methanol containing IS (0.03 μg/mL D5-EtG, ca. 0.005 μg/
mL D5-EtS) and subsequent mixing by vortexing for 5 min.
The methanolic solution was transferred to a vial and dried
under a gentle stream of nitrogen at 50 °C. The samples
were then reconstituted with 50 μL of a water/acetonitrile/
formic acid (95/5/0.1; v/v) solution and shaken for 1 min.
The reconstituted solution was transferred into restricted
volume vials and 10 μL was injected into the LC-MS/MS
system.
Chromatographic system
The chromatographic system and conditions employed for
the analysis were described earlier [29]. Instrumentation
consisted of a CTC PAL autosampler, an Agilent 1200 series
HPLC, and a QTrap 3200 mass spectrometer (AB Sciex,
Rotkreuz, Switzerland) controlled by Analyst 1.5.1 soft-
ware, which was also used for the data acquisition and
processing. For the analytical separation, a 150×2-mm col-
umn with 4 μm particles (Synergi Polar-RP, Phenomenex,
Torrance CA, USA) contained in a column heater at 40 °C
was used. To enhance signal intensity, 2-propanol was
added post-column with a flow of 0.3 mL/min by a T-
union before the eluent enters the electrospray ion source.
The gradient elution was performed with 0.1 % formic
acid in water as mobile phase A and 0.1 % formic acid in
acetonitrile as mobile phase B. The gradient was run at a
flow of 0.3 mL/min starting at 2 % B for 2 min and
increasing to 90 % B for 3 min. The gradient was then
changed back to the starting conditions over 0.5 min and
kept constant for 6.5 min to re-equilibrate. The retention
times of EtG and EtS were 1.96 and 1.66 min, respectively.
The mass spectrometer was operated in the negative
multiple reaction monitoring mode by employing a Tur-
boIonSpray source. The following transitions were moni-
tored: EtG: m/z 221/75 as quantifier, m/z 221/85 as qualifier,
and m/z 226/75 for the deuterated internal standard. EtS: m/z
125/97 as quantifier, m/z 125/80 as qualifier, and m/z 130/98
for the deuterated internal standard.
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Chemicals and materials
EtG and D5-EtG were obtained from Lipomed (Arlesheim,
Switzerland). Sodium EtS was purchased from ABCR (Karls-
ruhe, Germany). Deuterated EtS (D5-EtS) was synthesized by
an in-house procedure with a purity of >99.9 % [31]. Aceto-
nitrile supra gradient grade was obtained from Biosolve
(Chemie Brunschwig, Basel, Switzerland) and HPLC-grade
water was produced in-house with a Milli-Q water system
from Millipore (Billerica, USA). Formic acid (puriss p.a.,
98 %), methanol (spectrophotometric grade, ≥99 %), and
MiniPax Sorbent packages were purchased from Sigma-
Aldrich (Buchs, Switzerland). Bioanalysis cards number
226-1004 from PerkinElmer (Greenville, USA) were used
for dried blood spot collection and a home-made 1-cm-
diameter hole puncher was employed to cut out the dried
blood spots. Nine milliliters heparin S-Monovette was pur-
chased from Sarstedt (Nümbrecht, Germany). Drug-free lith-
ium heparin whole blood was obtained from six volunteers
who were abstinent from alcohol for at least 2 weeks.
Method validation
The analytical method for the determination of EtG and EtS
in DBS was validated according to the guidelines of the
GTFCh [30]. During the validation, all samples were pro-
cessed as DBS as described before. The evaluated parame-
ters were linearity, accuracy and precision, selectivity,
stability, and extraction efficiency. The accuracy was deter-
mined by calculating the percent deviation of the data from
the nominal concentration. The precision, which is usually
expressed as “imprecision,” was determined by calculating
the relative standard deviation (% RSD) [30].
The linearity of the method was tested by analyzing a six-
point calibration curve constructed on six different days in the
range 0.1–10 μg/mL. The intra- and inter-day precision and
accuracy were studied by analyzing replicate samples (n=2) at
two different concentration levels (0.3 and 6.6 μg/mL) over
eight different days (n=8). The selectivity of the method was
studied by analyzing blank blood from six different sources.
The stability of EtG and EtS in DBS was investigated by
storing collection cards with DBS spiked at 0.3 μg/mL and
at 6.6 μg/mL in sealable plastic bags that contained desic-
cant packages at room temperature and at 4 °C for 1, 2, and
3 weeks, respectively. The desiccant packages in the plastic
bags were replaced with new ones every week to protect the
specimens against humidity and moisture. For the two in-
vestigated QC levels and storage conditions, six replicates
(n=6) were analyzed on the first day and after the different
time periods given before.
The extraction efficiency of the method was calculated
by comparing the peak area ratios of the analytes/internal
standards (percent) between extraction and control samples
at each QC level. The control samples (n=6) were prepared
by extracting 10 μL of blank DBS samples with 500 μL of
methanol. Two hundred microliters of the methanolic solu-
tion was then transferred to a vial and 500 μL of the MeOH/
IS solution and 10 μL of a quality control sample prepared
in methanol were added. The mixtures were then evaporated
under a gentle stream of nitrogen at 50 °C and reconstituted
with 50 μL of a water/acetonitrile/formic acid (95/5/0.1; v/v)
solution. The extraction samples (n=6) were prepared by
extracting 10 μL of spiked DBS samples with 500 μL of
methanol. Two hundred microliters of the methanolic solu-
tion was then transferred to a vial and 500 μL of the MeOH/
IS solution was added. The mixtures were then evaporated
under a gentle stream of nitrogen at 50 °C and reconstituted
with 50 μL of a water/acetonitrile/formic acid (95/5/0.1; v/v)
solution.
Method comparison
To evaluate the DBS method for determination of EtG and
EtS, 76 heparinized blood samples from traffic offense cases
with blood alcohol concentrations ranging from 0.48 to
3.03‰ were analyzed as whole blood and as DBS samples
with a separate calibration for each analysis method. The
mean and median values of the results from each method
were compared for EtG and EtS. Further, the normal distri-
bution of the differences was tested using the Kolmogorov–
Smirnov test, and a matched-paired t test and Bland–Altman
analysis [32, 33] (which rely on the assumption of normally
distributed data) were performed. In addition, two further
statistical tests, which are valid for data from any distribu-
tion, were performed: Wilcoxon test and Mountain plot [34].
The matched-paired t test and Wilcoxon test show if there is
a significant mean difference between two sets of paired
data, whereas the Bland–Altman analysis and Mountain plot
offer simple and graphical methods to estimate the analyti-
cal error [34].
Results
Validation of the DBS method
The calibration curves were linear in the measured range
0.1–10 μg/mL and showed a mean correlation coefficient of
0.9980 and 0.9984 for EtG and EtS, respectively. They were
weighed (1/x) in order to avoid the data at the high end of
the calibration curve to dominate the calculation resulting in
excessive error in the low calibration range. The intra- and
inter-day precision and the accuracy met the requirements of
the GTFCh for validation of analysis methods for both QC
levels (Table 1). The lowest calibration level, 0.1 μg/mL,
was measured with an accuracy and precision (% RSD)
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smaller than 20 % and was therefore selected as the lowest
limit of quantification of the method (results not shown).
The selectivity of the method was studied by analyzing
blank blood from six different sources. No interfering peaks
for EtG or EtS were observed in any of the studied blank
DBS samples.
The stability of EtG and EtS in DBS was investigated
after storing the cards at room temperature and at 4 °C for 1,
2, and 3 weeks, respectively, as described in the experimen-
tal part. The results shown in Table 2 demonstrate that
EtG and EtS in DBS are stable for at least 3 weeks
when stored either at room temperature or at 4 °C: the
mean percentages found were within 85–115 % of the
results obtained when the samples were analyzed after a
3-h drying period.
The extraction efficiency was assessed by comparing
the peak area ratios of extracted and control QC samples
at low and high level (n=6) as described before. The
extraction efficiency for EtG and EtS from DBS was 43
and 48 %, respectively, for both tested concentration
levels. The reason for this relative low extraction effi-
ciency could be the irreversible binding of the analytes to
the filter paper since, as observed in Table 2, no decom-
position is observed after 3 weeks of storage neither at
room temperature nor at 4 °C.
Comparison of the results from whole blood and from DBS
samples
The EtG and EtS concentrations in blood ranged from 460 to
6,250 ng/mL (mean 2,179 ng/mL, median 1,885 ng/mL) and
from 200 to 2,720 ng/mL (mean 1,157 ng/mL, median
1,020 ng/mL), respectively. In DBS, the EtG and EtS concen-
trations ranged from 428 to 6,690 ng/mL (mean 2,126 ng/mL,
median 1,885 ng/mL) and from 161 to 2,680 ng/mL (mean
1,177 ng/mL, median 1,085 ng/mL), respectively.
The normal distribution of the differences was tested and
proofed for both analytes using the Kolmogorov–Smirnov
test (results not shown). Then, a matched-paired t test was
conducted in order to assess if there was a significant dif-
ference between the two methods in the determination of
EtG and EtS. The paired t test value calculated for EtG and
EtS was 1.982 and 1.718, respectively, lower than the t score
for a two-tailed distribution for a significance level of 0.05,
1.991. Thus, according to this test, there was no significant
difference between the two methods for any of the studied
analytes.
In addition, the Wilcoxon rank sum test was performed
which is valid for data from any distribution, whether nor-
mal or not, and for this reason less meaningful than the t test.
The calculated test and threshold values for a significance
level of 0.05 were 376 and 371, respectively, for EtG, and
456 and 364, respectively, for EtS. For both biomarkers, the
test values calculated with this test were higher than the
threshold values, indicating a significant difference in the
distribution of the differences.
Apart from these statistical tests, the Bland–Altman anal-
ysis was used to assess the agreement between the two
methods for EtG and EtS measurement and to determine if
the two methods match enough to be interchanged [32].
Taking into consideration the normal distribution of the
differences, as proofed by the Kolmogorov–Smirnov test,
the mean difference of the methods, the standard deviation
(SD), the limits of agreement, and the confidence intervals
(CI) were calculated as described in [33]. The limits of
agreement show a range of values where 95 % of the differ-
ences are expected to lie, whereas the confidence intervals
show a range in which the population values lie with 95 %
probability [33]. In order to estimate the impact of the
measured differences on the EtG and EtS analysis, these
Table 1 Precision (relative
standard deviation, % RSD) and
accuracy (percent deviation from
the nominal concentration) of
the DBS method determined
at low (0.3 μg/mL) and high
(6.6 μg/mL) EtG and EtS
concentrations
Nominal concentration EtG EtS
Low High Low High
Intra-day precision (% RSD, n=2) 6.1 4.4 6.6 6.5
Inter-day precision (% RSD, n=8) 7.5 7.6 6.3 7.8
Accuracy (n=16) 107.3 106.9 108.8 106.9
Table 2 Stability data of EtG and EtS in DBS stored at room temperature
and at 4 °C for 1, 2, and 3 weeks, respectively, presented as the mean
percentage±standard deviation of the results obtained when analyzed on
the first day
RT 4 °C
Low High Low High
EtG
1 week 102.3±8.1 93.0±6.6 101.5±6.1 98.6±9.0a
2 weeks 100.0±8.7 105.0±6.5 104.3±6.3 108.4±2.8
3 weeks 111.4±4.8b 105.0±5.5 115.2±8.4b 109.6±7.1
EtS
1 week 102.6±5.5 93.6±5.7 102.4±7.0 93.8±6.8
2 weeks 105.6±4.9 103.6±7.1 111.8±3.3 105.3±2.2
3 weeks 108.8±5.1b 103.1±3.6 108.7±6.1b 102.6±7.1
a n=5
b n=4
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parameters were calculated relative to the mean of the two
values, so the results are shown in percent.
The Bland–Altman plot in Fig. 1 shows a graphical
representation of the between-method percentage difference
(y-axis) versus the average of the two methods (x-axis),
since this is the best estimate of the true value [32]. For
EtG, the mean difference between the methods was 2.92 %
(SD 9.48 %), with limits of agreement of −15.7 and 21.5 %.
For EtS, the mean difference between the methods was
−1.79 % (SD 8.44 %), with limits of agreement of −18.3
and 14.8 %. The mean percentage difference and the 95 %
limits of agreement are graphically represented in Fig. 1 as
solid and dotted lines, respectively. The CI with a 95 %
probability for the mean percentage differences and for the
limits of agreement of EtG and EtS are shown in Table 3,
but not graphically represented for clarity reasons.
In addition to the Bland–Altman analysis, and as recom-
mended in the literature [34], the Mountain plot of the
percentage differences of EtG and EtS, also called “folded
empirical cumulative distribution,” was performed and is
shown in Fig. 2. For EtG, the Mountain is centered at
3.4 %, and 95 % of the differences lie between −15 and
27 %. For EtS, the Mountain is centered at −2.5 %, with
95 % of the differences between −16 and 20 %.
Discussion
In the study presented here, the influence of the hematocrit
effect on the accurate quantification of the analytes was
overcome by collecting a fixed volume of blood on the filter
cards and then punching a hole larger than the blood spots
[15, 35]. Only 10 μL of blood was used for the analysis of
these two alcohol biomarkers. This is a big reduction of the
amount of required blood compared to the whole blood
method where 50 μL of blood or more is necessary. To
compensate this sample down scaling, a concentration step
was introduced when reconstituting the extracts in order to
be able to quantify low EtG and EtS concentrations. In
addition, during method development, the optimal extrac-
tion time with methanol was studied. It was observed that
a)
b)
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Fig. 1 Bland–Altman difference plots for EtG (a) and EtS (b) of the
percentage differences between whole blood and DBS assays (n=76)
against the average obtained by the two assays. The solid lines are the
mean percentage differences, whereas the dashed lines indicate the
limits of agreement set to ±1.96 SD
Table 3 Confidence intervals (CI) for the mean percentage differences
and limits of agreement of EtG and EtS
EtG (%) EtS (%)
CImean difference 0.76 to 5.09 −3.72 to 0.14
CI+1.96 SD 17.8 to 25.3 11.4 to 18.1
CI−1.96 SD −19.4 to −11.9 −21.7 to −15.0
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Fig. 2 Mountain plot of the percentage differences of EtG (circles)
and EtS (triangles) between whole blood and DBS assays. The 2.5 or
97.5 percentile is represented in the figure by a dashed line
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the extraction time could be reduced from 30 to 5 min still
obtaining similar recovery for EtG and EtS.
As reported earlier [17, 36], the IS employed for quanti-
fication purposes were added to the elution solvent, even
though it is regarded by some authors as not entirely satis-
factory [26]. They claim that with this method the IS are not
integrated into the sample prior to the extraction process and
that therefore they might not correct for any variability
during the extraction process [26]. However, employing
other more laborious IS application techniques where the
IS was integrated into the DBS samples prior to extraction
showed to be only as good as the method employed in this
study. The DBS method for the determination of EtG and
EtS was successfully validated regarding linearity, accuracy
and precision, selectivity, stability, and extraction efficiency.
The results of the matched-paired t test show that there is
no significant difference between the two analytical methods
in the determination of EtG and EtS. However, the Wilcoxon
rank sum test indicates a significant difference between the
two methods for both analytes. Even though this test is less
meaningful than the t test due to the normal distribution of the
differences, it points out that the differences are on the bor-
derline between being significant and not significant.
This is confirmed by the Bland–Altman analysis and the
Mountain plot. As it can be seen in Figs. 1 and 2, the whole
blood and DBS method for EtG and EtS determination are
biased with respect to each other. However, the bias calculated
for EtG and EtS is 3.15 and −2.15 % (mean of the bias
calculated with the Bland–Altman analysis and the Mountain
plot), respectively, an acceptable error when measuring bio-
logical samples. The limits of agreement calculated with the
Bland–Altman analysis and the Mountain plot show that the
differences are between −18 and 27 % (mean of the limits of
agreement calculated with the Bland–Altman analysis and the
Mountain plot). However, as indicated in [34], the bias and
large differences measured with these plots may have nothing
to do with the analytical properties of the assay but with
misidentified samples or other such mistakes. For this reason
the matched-paired t test that takes into account possible out-
liers is the method of choice for method comparison. Most
probably, duplicate analysis of the traffic offense case samples
as DBS and elimination of outliers would give different
results. However, the viability of EtG and EtS determination
from DBS was demonstrated with these conditions, and the
authors considered performing duplicate analysis or excluding
outliers not necessary to proof this point.
Unlike DBS that are created with capillary blood obtained
by skin puncture, the DBS specimens that were used in this
study for method validation and comparison were created from
heparinized venous whole blood samples, the so-called dried
venous blood spots. Capillary blood differs from blood that is
obtained through venipuncture and is usually contaminated
with interstitial and intracellular fluids [37]. Due to the
potential differences between venous and capillary blood ana-
lyte concentrations, the use of “dried capillary blood spots”
should be preceded by a complete validation. The determina-
tion of EtG and EtS from capillary DBS would open up new
possibilities in detecting recent alcohol consumption. The
sample can be collected by people without medical back-
ground after an adequate training and in a controlled environ-
ment which avoids sample contamination, dilution, or sample
mix-up. So, DBS analysis for EtG and EtS could be applied in
fields like workplace monitoring, abstinence control, or drunk-
en driving, where the time between offense and whole blood
sampling would be rather long (several hours) and the ethanol
could already be eliminated.
Conclusion
In this study, a new analytical method was presented for the
quantification of two biomarkers of recent alcohol consump-
tion by using DBS instead of liquid blood samples. EtG and
EtS were analyzed in blood spots that were collected on filter
paper and left to dry—the so-called DBS. The method was
successfully validated according to the GTFCh guidelines,
which largely coincide with internationally accepted guide-
lines. A comparison with the routinely employed whole blood
method was performed. The statistical analysis revealed that
both methods for EtG and EtS determination did not differ
significantly, being the bias measured between whole blood
and DBS irrelevant in toxicological analysis. Thus, the pre-
sented DBS method should be regarded as a promising meth-
od to determine EtG and EtS in blood, with the great potential
of the method lying in the easy and inexpensive sample
collection, transportation, and storage and the great stability
of the biomarkers in DBS samples. In addition, phosphatidyl-
ethanol—an upcoming alcohol marker—can be analyzed
from the same sample collection device [27, 28].
Acknowledgments The authors would like to thank Korbinian Seitz
(University of Bern) for language editing and the Swiss National
Foundation for financial support.
References
1. Schmitt G, Aderjan R, Keller T, Wu M (1995) Ethyl glucuronide: an
unusual ethanol metabolite in humans. Synthesis, analytical data, and
determination in serum and urine. J Anal Toxicol 19(2):91–94
2. Skipper GE, Weinmann W, Thierauf A, Schaefer P, Wiesbeck G,
Allen JP, Miller M, Wurst FM (2004) Ethyl glucuronide: a bio-
marker to identify alcohol use by health professionals recovering
from substance use disorders. Alcohol Alcohol 39(5):445–449
3. Wurst FM, Skipper GE, Weinmann W (2003) Ethyl glucuronide—
the direct ethanol metabolite on the threshold from science to
routine use. Addiction 98(Suppl 2):51–61
774 Int J Legal Med (2013) 127:769–775
4. Litten RZ, Bradley AM, Moss HB (2010) Alcohol biomarkers in
applied settings: recent advances and future research opportunities.
Alcohol Clin Exp Res 34(6):955–967
5. Substance Abuse and Mental Health Services Administration
(SAMHSA) (2012) The role of biomarkers in the treatment of
alcohol use disorders. SAMHSA Advisory 11 (2)
6. Schmitt G, Droenner P, Skopp G, Aderjan R (1997) Ethyl glucu-
ronide concentration in serum of human volunteers, teetotalers,
and suspected drinking drivers. J Forensic Sci 42(6):1099–1102
7. Halter CC, Dresen S, Auwaerter V, Wurst FM, Weinmann W
(2008) Kinetics in serum and urinary excretion of ethyl sulfate
and ethyl glucuronide after medium dose ethanol intake. Int J
Legal Med 122(2):123–128
8. Hoiseth G, Bernard JP, Karinen R, Johnsen L, Helander A,
Christophersen AS, Morland J (2007) A pharmacokinetic study
of ethyl glucuronide in blood and urine: applications to forensic
toxicology. Forensic Sci Int 172(2–3):119–124
9. Helander A, Bottcher M, Fehr C, Dahmen N, Beck O (2009)
Detection times for urinary ethyl glucuronide and ethyl sulfate in
heavy drinkers during alcohol detoxification. Alcohol Alcohol 44
(1):55–61
10. Pragst F, Balikova MA (2006) State of the art in hair analysis for
detection of drug and alcohol abuse. Clin ChimActa 370(1–2):17–49
11. Pragst F, Rothe M, Moench B, Hastedt M, Herre S, Simmert D
(2010) Combined use of fatty acid ethyl esters and ethyl glucuro-
nide in hair for diagnosis of alcohol abuse: interpretation and
advantages. Forensic Sci Int 196(1–3):101–110
12. Morini L, Colucci M, Ruberto MG, Groppi A (2012) Determination
of ethyl glucuronide in nails by liquid chromatography tandem mass
spectrometry as a potential new biomarker for chronic alcohol
abuse and binge drinking behavior. Anal Bioanal Chem 402
(5):1865–1870
13. Guthrie R, Susi A (1963) A simple phenylalanine method for
detecting phenylketonuria in large populations of newborn infants.
Pediatrics 32:338–343
14. De Jesus VR, Mei JV, Bell CJ, Hannon WH (2010) Improving and
assuring newborn screening laboratory quality worldwide: 30-year
experience at the Centers for Disease Control and Prevention.
Semin Perinatol 34(2):125–133
15. Edelbroek PM, van der Heijden J, Stolk LM (2009) Dried blood
spot methods in therapeutic drug monitoring: methods, assays, and
pitfalls. Ther Drug Monit 31(3):327–336
16. van der Heijden J, de Beer Y, Hoogtanders K, Christiaans M, de
Jong GJ, Neef C, Stolk L (2009) Therapeutic drug monitoring of
everolimus using the dried blood spot method in combination with
liquid chromatography–mass spectrometry. J Pharm Biomed Anal
50(4):664–670
17. Garcia Boy R, Henseler J, Mattern R, Skopp G (2008) Determination
of morphine and 6-acetylmorphine in blood with use of dried blood
spots. Ther Drug Monit 30(6):733–739
18. Jantos R, Veldstra JL, Mattern R, Brookhuis KA, Skopp G (2011)
Analysis of 3,4-methylenedioxymetamphetamine: whole blood
versus dried blood spots. J Anal Toxicol 35(5):269–273
19. Ingels AS, De Paepe P, Anseeuw K, Van Sassenbroeck D, Neels H,
Lambert W, Stove C (2011) Dried blood spot punches for confir-
mation of suspected gamma-hydroxybutyric acid intoxications:
validation of an optimized GC-MS procedure. Bioanalysis 3
(20):2271–2281
20. Mei JV, Alexander JR, Adam BW, Hannon WH (2001) Use of
filter paper for the collection and analysis of human whole blood
specimens. J Nutr 131(5):1631S–1636S
21. McDade TW, Williams S, Snodgrass JJ (2007) What a drop can
do: dried blood spots as a minimally invasive method for integrat-
ing biomarkers into population-based research. Demography 44
(4):899–925
22. Li W, Tse FL (2010) Dried blood spot sampling in combination
with LC-MS/MS for quantitative analysis of small molecules.
Biomed Chromatogr 24(1):49–65
23. Kissinger PT (2011) Thinking about dried blood spots for phar-
macokinetic assays and therapeutic drug monitoring. Bioanalysis 3
(20):2263–2266
24. O'Broin SD, Kelleher BP, Gunter E (1995) Evaluation of factors
influencing precision in the analysis of samples taken from blood
spots on filter paper. Clin Lab Haematol 17(2):185–188
25. Holub M, Tuschl K, Ratschmann R, Strnadova KA, Muhl A,
Heinze G, Sperl W, Bodamer OA (2006) Influence of hematocrit
and localisation of punch in dried blood spots on levels of amino
acids and acylcarnitines measured by tandem mass spectrometry.
Clin Chim Acta 373(1–2):27–31
26. Abu-Rabie P, Denniff P, Spooner N, Brynjolffssen J, Galluzzo P,
Sanders G (2011) Method of applying internal standard to dried
matrix spot samples for use in quantitative bioanalysis. Anal Chem
83(22):8779–8786
27. Jones J, Jones M, Plate C, Lewis D (2011) The detection of 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanol in human dried
blood spots. Analytical Methods 3(5):1101–1106
28. Faller A, Richter B, Kluge M, Koenig P, Seitz HK, Thierauf A,
Gnann H, Winkler M, Mattern R, Skopp G (2011) LC-MS/MS
analysis of phosphatidylethanol in dried blood spots versus con-
ventional blood specimens. Anal Bioanal Chem 401(4):1163–1166
29. Hernandez Redondo A, Korber C, Konig S, Langin A, Al-Ahmad
A, Weinmann W (2012) Inhibition of bacterial degradation of EtG
by collection as dried urine spots (DUS). Anal Bioanal Chem 402
(7):2417–2424
30. German Society of Toxicological and Forensic Chemistry (GTFCh)
(2009) Anforderungen an die Validierung vonAnalysenmethoden. T +
K 76:185–208
31. Dresen S, Weinmann W, Wurst FM (2004) Forensic confirmatory
analysis of ethyl sulfate—a new marker for alcohol consumption—
by liquid-chromatography/electrospray ionization/tandem mass
spectrometry. J Am Soc Mass Spectrom 15(11):1644–1648
32. Bland JM, Altman DG (1986) Statistical methods for assessing
agreement between two methods of clinical measurement. Lancet 1
(8476):307–310
33. Mantha S, Roizen MF, Fleisher LA, Thisted R, Foss J (2000)
Comparing methods of clinical measurement: reporting standards
for Bland and Altman analysis. Anesth Analg 90(3):593–602
34. Krouwer JS, Monti KL (1995) A simple, graphical method to
evaluate laboratory assays. Eur J Clin Chem Clin Biochem 33
(8):525–527
35. Ingels AS, Lambert WE, Stove CP (2010) Determination of
gamma-hydroxybutyric acid in dried blood spots using a simple
GC-MS method with direct “on spot” derivatization. Anal Bioanal
Chem 398(5):2173–2182
36. Suyagh MF, Iheagwaram G, Kole PL, Millership J, Collier P,
Halliday H, McElnay JC (2010) Development and validation of a
dried blood spot-HPLC assay for the determination of metronida-
zole in neonatal whole blood samples. Anal Bioanal Chem 397
(2):687–693
37. Keevil BG (2011) The analysis of dried blood spot samples using
liquid chromatography tandem mass spectrometry. Clin Biochem
44(1):110–118
Int J Legal Med (2013) 127:769–775 775
